Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT Imaging in Advanced Melanoma
NCT05279027Phase 1Active, not recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Mar 2022
- Primary completion
- Jul 2026
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zirconium-89 crefmirlimab berdoxam in melanoma, sponsored by Abramson Cancer Center. Primary endpoints: Zirconium Zr 89 Crefmirlimab Berdoxa uptake at 21 days and Change in uptake post therapy at 21 days. Started Mar 2022; status: active, not recruiting.
02
Drugs
zirconium-89 crefmirlimab berdoxam
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05279027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279027.